B4GALNT1

Official Full Name

beta-1,4-N-acetyl-galactosaminyltransferase 1

Organism

Homo sapiens

GeneID

2583

Background

GM2 and GD2 gangliosides are sialic acid-containing glycosphingolipids. GalNAc-T is the enzyme involved in the biosynthesis of G(M2) and G(D2) glycosphingolipids. GalNAc-T catalyzes the transfer of GalNAc into G(M3) and G(D3) by a beta-1,4 linkage, resulting in the synthesis of G(M2) and G(D2), respectively. Three transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Feb 2013]

Synonyms

GALGT; SPG26; GALNACT; GalNAc-T;

Cat.No.	Product Name	Price

Cat.No.	Product Name	Price

Cat.No.	Product Name	Price

Cat.No.	Product Name	Price

Detailed Information

The B4GALNT1 gene encodes β-1,4-N-acetyl-galactosaminyltransferase 1 and is located on human chromosome 12q13.3. The encoded enzyme is a type II transmembrane protein predominantly localized to the Golgi apparatus membrane and represents a key enzyme in the ganglioside biosynthesis pathway. B4GALNT1 catalyzes the transfer of N-acetyl-galactosamine in a β-1,4 linkage onto specific glycosphingolipid acceptors, most notably the gangliosides GM3 and GD3, thereby directly synthesizing GM2, which can subsequently give rise to disialoganglioside GD2. Multiple transcript variants exist, encoding different protein isoforms that may differ in tissue distribution, enzymatic properties, or subcellular localization, allowing fine-tuned control of ganglioside expression across tissues. Gangliosides are sialylated glycosphingolipids enriched in neuronal cell membranes, playing essential roles in cell recognition, signal transduction, and adhesion, with B4GALNT1 acting as a central "switch" controlling their production.

Biological Significance

B4GALNT1's biological importance lies in its regulation of specific gangliosides, particularly GD2, which influences cellular physiology in both neural development and tumor biology. In the nervous system, gangliosides are critical components of neuronal membranes, participating in synapse growth, formation, and plasticity. GD2 exhibits spatiotemporally specific expression in normal neural tissues and is essential for neuronal development, differentiation, and functional maintenance. Proper regulation of B4GALNT1 activity is therefore crucial for normal neural development and function.

Outside the nervous system, GD2 is aberrantly overexpressed in multiple neuroectoderm-derived malignancies, including neuroblastoma, glioblastoma, osteosarcoma, and some melanomas and breast cancers. High GD2 expression is closely associated with aggressive tumor behavior, promoting proliferation, invasiveness, resistance to apoptosis, and immune evasion via interactions with the tumor microenvironment. Consequently, B4GALNT1, as the rate-limiting enzyme in GD2 synthesis, plays a pivotal role in driving these malignant phenotypes. Loss-of-function mutations in B4GALNT1 cause autosomal recessive spastic paraplegia type 26, a neurodegenerative disorder, underscoring the enzyme's critical role in maintaining normal motor neuron function.

Clinical Relevance

The B4GALNT1/GD2 axis is a clinically validated target in cancer immunotherapy. Given GD2's high tumor-specific expression and limited distribution in normal tissues (primarily neurons and melanocytes), it is an ideal therapeutic target. GD2-targeted monoclonal antibodies, such as dinutuximab, are standard treatment for high-risk neuroblastoma, functioning through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) to effectively eliminate GD2-positive tumor cells, significantly improving patient outcomes. GD2-directed chimeric antigen receptor (CAR) T cell therapies have also demonstrated potent antitumor activity in preclinical and early clinical studies, offering promise for other GD2-positive solid tumors.

Figure 1. Mechanisms of anti-GD2 mAbs and other therapeutic approaches. (Nazha B, et al., 2020)

Beyond therapy, B4GALNT1/GD2 serves as a diagnostic and prognostic biomarker. Immunohistochemical detection of GD2 in tumors aids in subtyping, prognostication, and identifying patients likely to benefit from anti-GD2 therapy. Future research directions include managing adverse effects such as pain associated with anti-GD2 therapy, overcoming tumor resistance to monotherapy, and extending these therapeutic strategies to additional GD2-positive cancers. For genetic conditions such as B4GALNT1-associated spastic paraplegia, there are currently no effective treatments, highlighting the need for mechanistic studies to develop targeted or disease-modifying interventions.

References

Ledeen RW, Wu G. Gangliosides, α-Synuclein, and Parkinson's Disease. Prog Mol Biol Transl Sci. 2018;156:435-454.
Li TA, Schnaar RL. Congenital Disorders of Ganglioside Biosynthesis. Prog Mol Biol Transl Sci. 2018;156:63-82.
Chan GC, Chan CM. Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma. Biomolecules. 2022 Feb 24;12(3):358.
Nazha B, Inal C, Owonikoko TK. Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy. Front Oncol. 2020 Jul 7;10:1000.

Quick Inquiry

Interested in learning more?

Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.

Request a quote today!

Inquiry